Ontology highlight
ABSTRACT: Background
Psoriasis severity and treatment responsiveness vary by body region, which differentially impacts quality of life (QoL).Objective
The objective of the study was to examine adalimumab efficacy by body region and regional response and QoL relationship.Methods
Patients (n = 1212) with moderate-to-severe psoriasis were randomized 2:1 to 80 mg at week 0, followed by adalimumab 40 mg or placebo every other week for 16 weeks in the double-blind REVEAL study. Psoriasis Area and Severity Index (PASI) responses and Dermatology Life Quality Index outcomes were analyzed.Results
Week 16 regional mean PASI improvements were significantly greater with adalimumab (83.1 ± 1.57, 81.3 ± 1.58, 75.7 ± 1.34, and 73.9 ± 1.26% in the trunk, head, upper extremities, and l
SUBMITTER: Armstrong AW
PROVIDER: S-EPMC5110581 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature